[1]
Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432-3.
[2]
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
[3]
Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-17.
[4]
Kuswanto WF, MacFarlane LA, Gedmintas L, Mulloy A, Choueiri TK, Bermas BL. Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum 2018; 47: 907-10.
[5]
Gediz F, Kobak S. Immune checkpoint inhibitors-related rheumatic diseases: What rheumatologist should know? Curr Rheumatol Rev 2019. Jan 18. [Epub ahead of print].
[6]
Sheik AS, Goddard AL, Luke JJ, et al. Drug-associated dermatomyositis following ipilimumab therapy: A novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015; 151: 195-9.
[7]
Khoja L, Maurice C, Chappell M, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016; 4: 175-8.
[8]
Bourgeois-Vionnet J, Joubert B, Bernard E, Sia MA, Pante V, Fabien N. Nivolumab-induced myositis: A case report and a literature review. J Neurol Sci 2018; 387: 51-3.
[9]
Gandiga PC, Wang AR, Gonzalez-Rivera T, Sreih AG. Pembrolizumab-associated inflammatory myopathy. Rheumatology (Oxford) 2018; 57(2): 397-8.
[10]
Narváez J, Juarez-López P. LLuch J, Narváez JA, Palmero R, García Del Muro X. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Autoimmun Rev 2018; 17(10): 1040-5.
[11]
Calabrese C, Kirchner E, Kontzias K, Velcheti V, Calabrese LH. Rheumatic immune-related adverse events of checkpoint therapy for cancer: Case series of a new nosological entity. RMD Open 2017; 3(1): e000412.
[12]
Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hans J. Inflammatory arthritis: A newly recognized adverse event of immune checkpoint blockade. Oncologist 2017; 22: 627-30.
[13]
Lidar M, Giat E, Garelick D, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018; 17(3): 284-9.
[14]
Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A. Muscloskeletal and rheumatic diseases induced by immune checkpoint inhibitors: A review of the literature. Curr Drug Saf 2018; 13(3): 150-64.
[15]
Liew DFL, Leung JLY, Liu B, Cebon J, Frauman AG, Buchanan RRC. Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. Int J Rheum Dis 2019; 22(2): 297-302.
[16]
Shafqat H, Gourdin T, Sion A. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy. Semin Oncol 2018; 45(3): 156-63.
[17]
Liepe J, Christ LA, Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 2018; 4(2): e000714.
[18]
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol 2016; 27(4): 559-74.
[19]
van der Vlist M, Kuball J, Radstake TR, Meyaard L. Immune checkpoints and rheumatic diseases: What can cancer immunotherapy teach us? Nat Rev Rheumatol 2016; 12: 593-604.
[20]
Kim ST, Tayar J, Trinh VA, et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: A case series. Ann Rheum Dis 2017; 76(12): 2061-4.
